ReviewWorld journal of pediatrics : WJP2026
Position statement of the Mexican Association of Pediatrics on the immunoprevention of respiratory syncytial virus infection during pregnancy and infancy.
Review in World journal of pediatrics : WJP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus infection is one of the leading causes of morbidity and mortality in children under two years of age. Thus, the objective of this consensus document is to analyze and discuss current scientific evidence and generate recommendations that reflect the position of a prominent national pediatric professional association regarding the benefits and impact of immunoprophylaxis in pregnant women and infants on the burden of respiratory syncytial virus-related respiratory disease in Mexico and Latin America. DATA SOURCES: Following an academic consensus model, the available scientific literature on current or controversial topics was compiled and critically analyzed. The process adhered to the Guidelines for the Development of Consensus Documents and incorporated recommendations and critical appraisal criteria from the European Appraisal of Guidelines for Research and Evaluation initiative. Multidisciplinary and representative teams were formed from several national professional associations. The studies and manuscripts included in this review were selected via keywords such as respiratory syncytial virus, vaccine, monoclonal antibodies, maternal vaccine, safety and efficacy in vaccine, and vaccine compliance across databases, with priority given to articles published between January 2019 and May 2025. The process included one in-person meeting and one virtual meeting.
resultsA total of nine questions, which were considered unresolved in previous respiratory syncytial virus-related consensus documents, were formulated, covering the time, dose, cost-effectiveness and other perspectives. Each one was addressed through an updated literature review and critical appraisal. The findings and resulting recommendations were presented along with their corresponding level of evidence according to Grading of Recommendations Assessment, Development, and Evaluation.
conclusionsBoth maternal respiratory syncytial virus vaccination (RSVpreF) and passive immunization with nirsevimab demonstrate robust efficacy and favorable safety, protecting newborns and infants from severe respiratory syncytial virus infections. The document provides actionable, evidence-based recommendations tailored for the Latin American healthcare context, aiming to reduce severe respiratory syncytial virus disease incidence and improve national infant health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.